How to store Cerebrolysin
An injectable pig brain mixture with mixed stroke, brain-injury and dementia evidence.
Also called: FPF-1070, Cerebrolysin concentrate.
Nootropic peptides · Porcine brain-derived peptide and amino-acid mixture · Evidence: Approved drug.
Comes as: Licensed amber liquid in glass ampoules or vials; 215.2 mg peptide fraction per mL, Austrian pack sizes: 1, 2, 5, 10, 20, 30 and 50 mL; availability varies.
Mixed with: Already liquid. Austria lists 0.9% saline, Ringer solution or 5% glucose for IV dilution. No powder mixing is needed..
- National prescribing information is represented as clinical-practice here; the schema reserves label for FDA/EMA.
- Ampoules have 48-month shelf life; 20, 30 and 50 mL puncturable vials have 24 months, when stored as specified.
- Austrian limits: up to 5 mL IM, up to 10 mL IV; infusion recommended from 10 mL, over about 15–60 minutes.
- Use only clear amber solution. Sodium hydroxide and water for injection are listed excipients.
- Milligram-labeled powder has no established conversion to the licensed liquid; 215.2 mg/mL does not establish product equivalence.
- This field does not validate community powder mixing or nasal-spray storage.
Before mixing: Austrian national SmPC: below 25°C, protected from light in the original pack. Do not refrigerate or freeze.
After mixing: Single withdrawal only; discard leftovers immediately. Tested 24-hour compatibility does not establish safe storage after opening.
Related to Cerebrolysin
- Semax: A Russian nasal peptide with limited human evidence for brain and nerve effects.
- Selank: A Russian nasal anxiety peptide with uncertain long-term benefit and safety.
- PE-22-28: An experimental mood peptide studied in mice, with no human trials found.
- Dihexa: An experimental memory compound with disputed animal research and no established human dose.
- P21: An experimental memory peptide with animal research and no established human dose or safety profile.
- BPC-157: An experimental repair peptide with mostly animal evidence and a few small human reports.
Sources
- 21 CFR 216.23 — Bulk drug substances that can be used to compound drug products in accordance with section 503A of the Federal Food, Drug, and Cosmetic Act., Office of the Federal Register · eCFR · 2026
- 503B Bulk Drug Substances List, FDA · FDA · 2026
- Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act, FDA · FDA · 2026
- Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act, FDA · FDA · 2026
- MHRA Products | Home, MHRA · MHRA · 2026
- TGA strengthens compliance focus on unapproved peptide products as part of evolving risk response, Therapeutic Goods Administration · TGA · 2026
- The 2026 Prohibited List, World Anti-Doping Agency · WADA · 2026
- Therapeutic Goods (Poisons Standard—October 2026) Instrument 2026, Australian Government · Australian Government · 2026
- Using intramuscular injections in people on oral anticoagulants, NHS Specialist Pharmacy Service · NHS Specialist Pharmacy Service · 2023
- European Academy of Neurology and European Federation of Neurorehabilitation Societies guideline on pharmacological support in early motor rehabilitation after acute ischaemic stroke., Beghi E et al. · European journal of neurology · 2021
- Tailor Made Compounding LLC - 594743 - 04/01/2020, FDA · FDA · 2020
- Q6A Specifications: Test Procedures and Acceptance Criteria for New Drug Substances and New Drug Products: Chemical Substances, FDA · FDA · 2000
- CEREBROLYSIN, BASG
- Drug Product Database online query, Health Canada
- PHARMACY & POISONS BOARD OF HONG KONG | 香港藥劑業及毒藥管理局, Hong Kong Department of Health
Sources checked: 2026-10-18.
Information only, not medical advice. Peptifacts does not sell anything and does not link to sellers.